Jacob S. Sherkow (@jsherkow@mastodon.lawprofs.org) (@jsherkow) header
Jacob S. Sherkow (@jsherkow@mastodon.lawprofs.org) (@jsherkow) profile picture

Jacob S. Sherkow (@[email protected])

@jsherkow

Prof @UIllinoisLaw, @IllinoisMed, @IGBIllinois, @eucenter; also @CeBIL_Center #patents, #IP, #biotech, #pharma, #bioethics. Ducks, drugs, and nicks that roll.

 Champaign, IL
law.illinois.edu/faculty-research/faculty-profiles/jacob-s-sherkow/
Joined August 2012
  • Tweets14.2K
  • Following284
  • Followers4.6K
720Media
Photo by Jacob S. Sherkow (@jsherkow@mastodon.lawprofs.org) (@jsherkow)Photo by Jacob S. Sherkow (@jsherkow@mastodon.lawprofs.org) (@jsherkow)Photo by Jacob S. Sherkow (@jsherkow@mastodon.lawprofs.org) (@jsherkow)Photo by Jacob S. Sherkow (@jsherkow@mastodon.lawprofs.org) (@jsherkow)Photo by Jacob S. Sherkow (@jsherkow@mastodon.lawprofs.org) (@jsherkow)Photo by Jacob S. Sherkow (@jsherkow@mastodon.lawprofs.org) (@jsherkow)Photo by Jacob S. Sherkow (@jsherkow@mastodon.lawprofs.org) (@jsherkow)Photo by Jacob S. Sherkow (@jsherkow@mastodon.lawprofs.org) (@jsherkow)Photo by Jacob S. Sherkow (@jsherkow@mastodon.lawprofs.org) (@jsherkow)Photo by Jacob S. Sherkow (@jsherkow@mastodon.lawprofs.org) (@jsherkow)
Goodbye, Twitter! jsherkow.web.illinois.edu/20…
5
1
2
4
Jacob S. Sherkow (@[email protected]) retweeted
JP (@ActuallyyJP) profile picture
JP@ActuallyyJP18 Feb 2022
Academics on their side projects
Image from JP (@ActuallyyJP)
23
341
179
3,028
1/ OK, everyone, buckle up. @RESachs and I have a piece @TheAtlantic about Aduhelm. It's about how the law links FDA approval to payment policy, which means we're likely to spend through the nose for a drug that may not work. theatlantic.com/ideas/archiv…
Image from Nicholas Bagley (@nicholas_bagley)
13
142
69
320
The FDA's approval of Aduhelm is a big fucking deal, and not in a good way, as @RESachs explains here: healthaffairs.org/do/10.1377…
The FDA’s Approval Of Aduhelm: Potential Implications Across A Wide Range Of Health Policy Issues...

The FDA’s Approval Of Aduhelm: Potential Implications Across A Wide Range Of Health Policy Issues...

It is rare for an FDA approval decision to have the potential to fundamentally reshape many different aspects of health care policy, but the agency’s decision to approve Aduhelm so broadly could do...

healthaffairs.org
14
1
43
Everything you need to know about when you could get a Covid-19 vaccine and how, by ⁦@Loftus⁩ and ⁦@betswrites⁩ wsj.com/articles/the-covid-1…
The Covid-19 Vaccine: When Will It Be Available for You?

The Covid-19 Vaccine: When Will It Be Available for You?

This is what we know and don’t know about how, and when, the coronavirus vaccine is likely to reach Americans, from high-risk people and essential workers to those in the general population.

wsj.com
2
4
.@PennMedicine scientist Drew Weissman talked to @CNN's @drsanjaygupta about how the mRNA tech he developed at Penn will help save the world from #COVID19 and revolutionize medicine cnn.it/2HBlmDR
1
6
1
9
Not my area but a really interesting online symposium:
Women Also Know Law (@womenknowlaw) profile pictureWomen Also Know Law@womenknowlaw24 Nov 2020
Check out @UChiLRev's online symposium on COVID-19 and Criminal Justice featuring essays by Professors @SharonDolovich, @valenabeety, @ProfPamMetzger and @jenndoliva! buff.ly/2KpjGhB #WomenAlsoKnowLaw
Image from Women Also Know Law (@womenknowlaw)
1
Perspectives on Biohackers and DIY CRISPR ipscell.com/2020/11/perspect…
Perspectives on Biohackers and DIY CRISPR - The Niche

Perspectives on Biohackers and DIY CRISPR - The Niche

How should we view biohackers and their DIY use of CRISPR outside of the traditional industry or academic lab environment? 

ipscell.com
1
3
4
Always read @RESachs on drug pricing proposals. healthaffairs.org/do/10.1377…
4
5
As we approach Thanksgiving, just wanted to give thanks to everyone at @HarvardEthics for the incredible year last year. Miss you all! Hope we can see each other again, soon.
Image from Jacob S. Sherkow (@jsherkow@mastodon.lawprofs.org) (@jsherkow)
1
4
A third Covid-19 vaccine, this one developed by AstraZeneca and the University of Oxford, was found to be effective. ⁦@jennystrasburg⁩ reports this candidate was as much as 90% effective depending on the dosing. wsj.com/articles/astrazeneca…
AstraZeneca-Oxford Covid-19 Vaccine Up to 90% Effective in Late-Stage Trials

AstraZeneca-Oxford Covid-19 Vaccine Up to 90% Effective in Late-Stage Trials

The success of the vaccine being developed by the University of Oxford and AstraZeneca bodes well for the near-term availability of a third treatment for Covid-19, joining those from Moderna as well...

wsj.com
2
6
14
Mark your calendars for Dec. 10. Pfizer meets VRBPAC fda.gov/news-events/press-an…
1
6
2
14
Jacob S. Sherkow (@[email protected]) retweeted
U.S. FDA (@FDA) profile picture
U.S. FDA
@FDA20 Nov 2020
We have scheduled a meeting of our Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 10th to discuss an emergency use authorization request for a #COVID19 vaccine. fda.gov/news-events/press-an…
Image from U.S. FDA (@FDA)
50
82
66
152
If this external VRBPAC review of the 1st vaccine goes well, we'll likely see Phase 1a distribution begin right after December 10th fda.gov/news-events/press-an… nap.edu/download/25917
Image from Eric Topol (@EricTopol)
18
133
40
477
In the spring, everyone said it would take 12 to 18 months for a vaccine. Here’s the improbable tale of how Moderna, Pfizer, BioNTech and a massive federal effort drastically shortened that timeline. nytimes.com/2020/11/21/us/po…
Politics, Science and the Remarkable Race for a Coronavirus Vaccine (Published 2020)

Politics, Science and the Remarkable Race for a Coronavirus Vaccine (Published 2020)

The furious race to develop a coronavirus vaccine played out against a presidential election, between a pharmaceutical giant and a biotech upstart, with the stakes as high as they could get.

nytimes.com
6
38
6
101
Covid-19 antibody drug from Regeneron is authorized by ⁦@US_FDA⁩, the second such antibody drug to gain clearance. Story coming to ⁦@WSJ⁩... fda.gov/news-events/press-an…
Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19

Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19

The FDA issued an EUA for two monoclonal antibodies to be administered together for treating mild to moderate COVID-19 in adults and pediatric patients.

fda.gov
1
11
4
14
🦆 ALL HAIL LONG BOI 🦆 The final results: Long Boi - 2,182 Lancaster Ducks - 2,090 SWANsea Swans - 1,048 Cath the OU Duck - 774 See the full table at bantshire.github.io/ranking-…
Image from Bantshire University (@BantshireUni)
9
66
64
447
How should #innovation policymakers think about #AI—and its biases—in addressing #COVID? A new WD Post from @WNicholsonPrice, @RESachs, me & @PatentScholar writtendescription.blogspot.…
4
3
Check out this excellent tweet thread on public funding of drug innovation!
This Post is from an account that no longer exists. Learn more
4
5
WOOOOOOOT!
STAT (@statnews) profile pictureSTAT
@statnews20 Nov 2020
The drug maker Pfizer and its German partner BioNTech said Friday afternoon they have applied to the FDA for an emergency use authorization for their Covid-19 vaccine. buff.ly/36VniiV #Pfizer #BioNTech #COVID19 #vaccine
2
Load more